Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient

Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient

Blog Article

BackgroundPosttransplant lymphoproliferative cyspera cream where to buy disorders (PTLDs) are uncommon but serious complications in patients following solid organ transplantation.Primary Epstein-Barr virus (EBV) infection is a risk factor for the development of PTLD, especially early-onset PTLD, in EBV-negative recipients.To date, however, there are no specific guidelines on the threshold of EBV-DNA load for therapeutic intervention, the source for measurement (e.g., blood, bronchoalveolar fluid), or the use of antiviral agents as prophylaxis for early PTLD prevention in EBV-mismatched patients.

MethodsThe present study describes a 56-year-old male lung transplant recipient diagnosed with EBV-associated PTLD.ResultsThis patient had a history of invasive fungal disease and Mucor and Aspergillus fumigatus infections in the early post-transplant period, necessitating antifungal therapy throughout the course of the disease.The patient was EBV-positive 15 neflintw-r6mpw days after transplantation, with lung CT showing multiple bilateral nodules of varying sizes beginning 98 days after transplantation.A lung biopsy showed PTLD, and next-generation sequencing (NGS) revealed EBV.This patient, however, did not receive any antiviral therapy for early PTLD prevention or any PTLD-related treatment.

He died 204 days after lung transplantation.ConclusionThe present study describes a lung transplant recipient who developed EBV-associated PTLD, a non-negligible disease, after solid organ transplantation.Monitoring EBV-DNA load is important, as a sudden increase may be a sensitive indicator of PTLD.An earlier diagnosis may increase the likelihood of successful treatment.